← FDA DRUG APPROVALS

FDA ANDA · ANDA207678

SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE

Sponsor: DR REDDYS LABS SA

APPLICATION
ANDA207678
TYPE
ANDA
ORIGINAL APPROVAL
2023-08-09
LATEST ACTION
2023-08-09
ROUTE
ORAL
DOSAGE FORM
TABLET, EXTENDED RELEASE
MARKETING STATUS
Prescription

Products

SAXAGLIPTIN AND METFORMIN HYDROCHLORIDEPrescription
METFORMIN HYDROCHLORIDE 1GM, SAXAGLIPTIN HYDROCHLORIDE EQ 2.5MG BASE · TABLET, EXTENDED RELEASE · ORAL
SAXAGLIPTIN AND METFORMIN HYDROCHLORIDEPrescription
METFORMIN HYDROCHLORIDE 1GM, SAXAGLIPTIN HYDROCHLORIDE EQ 5MG BASE · TABLET, EXTENDED RELEASE · ORAL
SAXAGLIPTIN AND METFORMIN HYDROCHLORIDEPrescription
METFORMIN HYDROCHLORIDE 500MG, SAXAGLIPTIN HYDROCHLORIDE EQ 5MG BASE · TABLET, EXTENDED RELEASE · ORAL

Approval history

2023-08-09UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →